Lexaria Bioscience’s (LEXX) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Lexaria Bioscience (NASDAQ:LEXX – Free Report) in a research report report published on Monday,Benzinga reports. HC Wainwright currently has a $10.00 target price on the stock. HC Wainwright also issued estimates for Lexaria Bioscience’s Q1 2025 earnings at ($0.12) EPS, Q2 2025 earnings at ($0.11) EPS, […]
More Stories
Skip the Spa: Achieving Relaxation with a Backyard Sauna Kit
A luxurious spa visit is no longer necessary for those seeking a tranquil and calming environment for relaxation. Many homeowners...
Types of Kitchen Faucets: A Quick Buyer’s Guide to Find the Perfect Sink Fit
Choosing kitchen faucets can be a little decision to make, yet it can have a tremendous impact on the appearance...
Significant Increase in the Circulation of Counterfeit Bills in Retail Stores
By The Canadian Press The Retail Council of Canada is sounding the alarm about the significant increase in circulation of...
White House Economist Proposal Coming Soon on $2,000 Tariff Rebate Checks
By Jack Phillips A top White House economic official said that it appears more and more likely that the Trump...
Malicious Actors Impersonating Senior US Officials, FBI Warns
By Naveen Athrappully Malicious actors are impersonating government officials to secure sensitive information and steal funds, the FBI said in...
DOJ Says It Re-released 119 Pages of Epstein Files That Were Redacted
By Jack Phillips The Department of Justice (DOJ) on Sunday re-released with “minimal redactions” 119 pages of grand jury materials...